GlobeNewswire Inc.··NaRegeneron's Fianlimab Melanoma Trial Misses Key Milestone in Competitive Setback
Regeneron's fianlimab-cemiplimab combination narrowly missed primary melanoma trial endpoint, showing 5.1-month PFS benefit but failing statistical significance.
REGNclinical trial failurePhase 3 trial